Key facts
- Alphina Therapeutics’s last known valuation is $22.5M (Apr 2021).
- It has raised $46.7M across 1 recorded rounds; the latest was Early Stage VC ($16.9M) in Sep 2021.
- Notable investors include Connecticut Innovations, Alexandria Venture Investments, Canaan Partners, Osage University Partners, HighCape Capital.
- Alphina Therapeutics has filed 1 Form D with the SEC, most recently Sep 2021 ($16.9M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Alphina Therapeutics
Funding rounds
1 roundsAbout Alphina Therapeutics
Developer of a healthcare technology intended for the treatment of a range of solid tumor indications. The company offers approaches to identify and characterize altered states metabolism and flux for selective tumor targeting over normal tissue, enabling biomarkers to develop new classes of drugs and therapies that target defects in cancer.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2018
- Employees
- 12
- Website
- alphinatx.com/
- Ownership
- Privately Held (backing)
Alphina Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alphina Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alphina Therapeutics in its N-PORT filings yet. We sweep new filings monthly.